RecruitingNot ApplicableNCT05558605
Use of Artificial Intelligence-Guided Echocardiography to assIst cardiovascuLar Patient managEment
Sponsor
Baker Heart and Diabetes Institute
Enrollment
612 participants
Start Date
Feb 24, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Heart Failure and valvular heart disease are disproportionate problems in rural and remote Australia (RRA). Echocardiography is the best imaging investigation, and essential for management, but access to this essential test shows huge geographic variations, primarily because of dependence on expert acquisition. This trial seeks to demonstrate the effectiveness of artificial intelligence-based echocardiography for triage and management of patients with known or suspected heart disease in RRA.
Eligibility
Min Age: 45 Years
Inclusion Criteria3
- Age \>45 years
- eligible for Medicare
- exercise intolerance or cardiovascular (CV) risk factors
Exclusion Criteria4
- Known HF or HVD
- situations where cardio-protection is already indicated (eg. known CAD)
- comorbid conditions with life expectancy \<2 years
- inability to provide written informed consent
Interventions
DIAGNOSTIC_TESTStandard echo
Standard echocardiography
DIAGNOSTIC_TESTAI-guided echo
AI-guided echocardiography
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05558605
Related Trials
Mind Your Heart-II
NCT054311921 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location